News

NEW YORK, NY, April 18, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May

NEW YORK, NY, April 13, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY and RYE BROOK, NY, March 28, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced a charitable commitment totaling $7.5 million to The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer.

NEW YORK, NY, March 3, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at

NEW YORK, NY, February 16, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m. ET. Royalty Pharma senior executives will present on the outlook for royalty funding in life sciences

NEW YORK , NY,  February 15, 2022  - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure) guidance.

NEW YORK, NY, January 20, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at

NEW YORK, NY and SOUTH SAN FRANCISCO, CA, January 7, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv 

NEW YORK, NY, January 6, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company’s quarterly dividend over the previous quarter’s dividend.